Teleflex Incorporated $TFX Holdings Boosted by JPMorgan Chase & Co.

JPMorgan Chase & Co. raised its stake in Teleflex Incorporated (NYSE:TFX) by 41.5% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 123,343 shares of the medical technology company’s stock after acquiring an additional 36,178 shares during the period. JPMorgan Chase & Co.’s holdings in Teleflex were worth $15,092,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. MassMutual Private Wealth & Trust FSB raised its position in shares of Teleflex by 57.9% during the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 210 shares of the medical technology company’s stock worth $26,000 after purchasing an additional 77 shares during the period. Hantz Financial Services Inc. boosted its position in Teleflex by 248.8% during the 3rd quarter. Hantz Financial Services Inc. now owns 279 shares of the medical technology company’s stock valued at $34,000 after purchasing an additional 199 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new position in Teleflex during the 3rd quarter worth $35,000. Quent Capital LLC bought a new position in Teleflex during the 3rd quarter worth $38,000. Finally, Cullen Frost Bankers Inc. increased its position in Teleflex by 496.7% in the third quarter. Cullen Frost Bankers Inc. now owns 358 shares of the medical technology company’s stock worth $44,000 after buying an additional 298 shares during the period. 95.62% of the stock is owned by institutional investors.

Teleflex Trading Up 2.1%

Shares of TFX stock opened at $110.48 on Friday. Teleflex Incorporated has a 1 year low of $100.18 and a 1 year high of $141.91. The firm has a market capitalization of $4.88 billion, a PE ratio of -5.38, a price-to-earnings-growth ratio of 0.67 and a beta of 0.87. The stock has a fifty day moving average of $108.80 and a two-hundred day moving average of $116.86. The company has a debt-to-equity ratio of 0.81, a quick ratio of 2.01 and a current ratio of 2.54.

Teleflex (NYSE:TFX) last issued its quarterly earnings results on Thursday, February 26th. The medical technology company reported $1.93 EPS for the quarter, missing analysts’ consensus estimates of $3.73 by ($1.80). Teleflex had a negative net margin of 30.56% and a positive return on equity of 14.30%. The business had revenue of $569.00 million for the quarter, compared to analyst estimates of $912.57 million. During the same period last year, the business posted $3.89 earnings per share. Teleflex’s revenue for the quarter was down 28.5% on a year-over-year basis. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. As a group, research analysts expect that Teleflex Incorporated will post 13.98 EPS for the current year.

Teleflex Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Friday, March 6th will be given a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date is Friday, March 6th. Teleflex’s payout ratio is -6.62%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Needham & Company LLC boosted their price target on shares of Teleflex from $138.00 to $147.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Royal Bank Of Canada increased their price objective on shares of Teleflex from $115.00 to $125.00 and gave the stock a “sector perform” rating in a report on Friday, February 27th. Wells Fargo & Company lifted their price objective on shares of Teleflex from $116.00 to $130.00 and gave the company an “equal weight” rating in a research report on Friday, February 27th. Wall Street Zen lowered shares of Teleflex from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Finally, Zacks Research cut shares of Teleflex from a “hold” rating to a “strong sell” rating in a research report on Monday, March 2nd. Two research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $140.83.

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.